Table 3.

Cognitive decline in and MCI participants with PET-Aβ stages 0, 1, and 2

Sample	Outcome	PET-Aβ stage	Annual Slope	P value
			points/y (/30)
ADNI and HABS MCI	Longitudinal	Stage 0	−0.074	0 vs. 1, P = .003
	MMSE	Stage 1	−0.251	1 vs. 2, P = e−40
		Stage 2	−1.164
			points/y (/30)
ADNI and HABS CN	Longitudinal	Stage 0	−0.037	0 vs. 1, P = .002
	MMSE	Stage 1	−0.156	1 vs. 2, P = .026
		Stage 2	−0.275
			z-scores/y
ADNI MCI	Longitudinal	Stage 0	−0.016	0 vs. 1, P = .013
	Memory Factor score	Stage 1	−0.076	1 vs. 2, P = e−22
		Stage 2	−0.344
			z-scores/y
ADNI CN	Longitudinal	Stage 0	+0.011	0 vs. 1, P = .014
	Memory Factor score	Stage 1	−0.074	1 vs. 2, P = .267
		Stage 2	−0.141
			z-scores/y
ADNI MCI	Longitudinal	Stage 0	+0.037	0 vs. 1, P = 6*e−5
	Executive Factor score	Stage 1	−0.053	1 vs. 2, P = 6*e−9
		Stage 2	−0.203
			z-scores/y
ADNI CN	Longitudinal	Stage 0	−0.013	0 vs. 1, P = .293
	Executive Factor score	Stage 1	−0.048	1 vs. 2, P = .015
		Stage 2	−0.188
			z-scores/y
HABS CN	Longitudinal	Stage 0	+0.053	0 vs. 1, P = .001
	PACC	Stage 1	−0.034	1 vs. 2, P = .006
		Stage 2	−0.125
			points/y (/30)
ADNI and HABS CN and MCI		Stage 0	−0.070	0 vs. 1+, P = .027
	Longitudinal	Stage 1+	−0.154	1+ vs. 1++, P = .001
	MMSE	Stage 1++	−0.410	1++ vs. 2+, P = .022
		Stage 2+	−0.625	2+ vs. 2++, P = 2*e−5
		Stage 2++	−0.930

Abbreviations: Aβ, amyloid β; ADNI, Alzheimer’s Disease Neuroimaging Initiative; CN, clinically normal; HABS, Harvard Aging Brain study; MCI, mild cognitive impairment; PACC, Preclinical Alzheimer Cognitive Composite.

NOTE. Longitudinal cognition by baseline PET-Aβ stages, adjusted for demographics (cohort and clinical diagnosis when applicable). Each box gives the result of a different linear mixed model. For transforming MMSE points in z-scores, divide slope by 1.18 (baseline SD of MMSE in CN). PACC is only available in HABS CN. See text for definition of the different stages. See Figs. 2 and 3 for illustrations using MMSE.